Resolving the Interference of Anti‐CD38 Antibodies on Blood Compatibility Assays Using CD38 “Baitbodies” Approach Blood transfusion safety depends on swift blood compatibility testing. Alloantibodies recognizing these blood group antigens determine blood compatibility, and the transfusion of incompatible blood c...

A CD38 "baitbody" to support safe blood products for multiple myeloma patients receiving Daratumumab and Isatuximab.
onlinelibrary.wiley.com/doi/full/10....

#baitbody, #daratumumab, #felzartamab, #isatuximab, #transfusionmedicine, #antibody, #fusionprotein, #bloodcompatability, #CD38, #MM

Significant Growth Expected in Antibody-Mediated Rejection Market by 2034 Driven by New Therapeutics The antibody-mediated rejection market is set for robust expansion over the next decade, as advances in treatment and diagnostics support increased transplant success.

Significant Growth Expected in Antibody-Mediated Rejection Market by 2034 Driven by New Therapeutics #None #imlifidase #Antibody-mediated_Rejection #Felzartamab

Randomized, Double-Blind, Placebo-Controlled Phase 2a Study Assessing the Efficacy and Safety of Felzartamab for IgA Nephropathy

doi.org/10.1016/j.kint.2025.05.028

#OpenAccess #IgAN #felzartamab #IgANephropathy

PREVAIL Investigator on Felzartamab’s Potential to Change IgAN Therapy | Docwire News Dr. George Newman of Knoxville Kidney Center discussed the PREVAIL study of felzartamab for IgA nephropathy (IgAN). Dr. Newman is a site PI for the trial.

CHECK OUT our interview with Dr. George Edward Newman, a PI for the #PREVAIL trial of #felzartamab for #IgAN. His Knoxville site recently dosed its first patient. #nephrology #nephsky #iganephropathy www.docwirenews.com/post/prevail...

10/10
Final thoughts🤔

⭐ Phase 2 study which showed acceptable safety profile of #felzartamab in late AMR

⭐ Efficacy outcomes may seem promising but need confirmation in phase 3 trial, powered to detect the same

#NephJC

7/10
#NephJC Chat consensus?

1️⃣ Phase 2 study : commenting on efficacy isn't wise
2️⃣ #Felzartamab still showed some efficacy in improving biochemical & pathological parameters in active AMR
3️⃣ Look out for ⬆️TCMR & late AMR post drug cessation
4️⃣ Looking forward to Phase 3 RCT🤞!

4/10
1 post, results

⚠️ Infusion reactions in 8/11 in trial arm
⚠️ SAE in 1/11 vs 4/11 in placebo
😃 Resolution of morphologic AMR in 82% vs 20%
📉 MVI score, ddcfDNA, molecular transcripts at 24 weeks
😐 AMR recurrence in 3/9 patients who had resolution with #felzartamab

#NephJC